{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:24:47Z","timestamp":1765232687441},"reference-count":88,"publisher":"Elsevier","isbn-type":[{"value":"9780444642776","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmch.2018.12.003","type":"book-chapter","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T10:34:13Z","timestamp":1549017253000},"page":"119-156","source":"Crossref","is-referenced-by-count":11,"title":["Rewriting the (tran)script: Application to spinal muscular atrophy"],"prefix":"10.1016","author":[{"given":"Hasane","family":"Ratni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/bs.pmch.2018.12.003_bb0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd.2018.93","article-title":"Principles for targeting RNA with drug-like small molecules","volume":"17","author":"Warner","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.003_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"Opinion: the druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.003_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"5\u20136","key":"10.1016\/bs.pmch.2018.12.003_bb0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cbpa.2009.08.003","article-title":"Identifying druggable disease-modifying gene products","volume":"13","author":"Dixon","year":"2009","journal-title":"Curr Opin Chem Biol"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.003_bb0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd.2017.239","article-title":"Small molecules against RNA targets attract big backers","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/bs.pmch.2018.12.003_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a016071","article-title":"Origin of spliceosomal introns and alternative splicing","volume":"6","author":"Irimia","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and regulation of alternative pre-mRNA splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu Rev Biochem"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.003_bb0050","doi-asserted-by":"crossref","first-page":"141\/1","DOI":"10.1186\/gb4145","article-title":"The spliceosomal catalytic core arose in the RNA world\u2026 or did it?","volume":"14","author":"Doolittle","year":"2013","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.003_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1101\/gad.209759.112","article-title":"Pick one, but be quick: 5\u2032 splice sites and the problems of too many choices","volume":"27","author":"Roca","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1451","article-title":"Rules and tools to predict the splicing effects of exonic and intronic mutations","volume":"9","author":"Ohno","year":"2018","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.003_bb0065","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1242\/jcs.181008","article-title":"Nonsense-mediated mRNA decay in humans at a glance","volume":"129","author":"Kurosaki","year":"2016","journal-title":"J Cell Sci"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.003_bb0070","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/EC.00090-14","article-title":"Regulation of natural mRNAs by the nonsense-mediated mRNA decay pathway","volume":"13","author":"Peccarelli","year":"2014","journal-title":"Eukaryot Cell"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.003_bb0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrn.2016.27","article-title":"The neurogenetics of alternative splicing","volume":"17","author":"Vuong","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg.2015.3","article-title":"RNA mis-splicing in disease","volume":"17","author":"Scotti","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0085","series-title":"Spinal muscular atrophy: disease mechanism and therapy","year":"2016"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of spinal muscular atrophies","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","article-title":"The neurobiology of childhood spinal muscular atrophy","volume":"3","author":"Crawford","year":"1996","journal-title":"Neurobiol Dis"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01776636","article-title":"Zwei fruhinfantile hereditare Falle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage","volume":"22","author":"Werdnig","year":"1891","journal-title":"Arch Psychiatr"},{"issue":"6","key":"10.1016\/bs.pmch.2018.12.003_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Uber chronische spinale Muskelatrophie im Kindersalter auf familiar basis","volume":"3","author":"Hoffmann","year":"1893","journal-title":"Dtsch Z Nervenheilkd"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.003_bb0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archneurpsyc.1956.02330230050005","article-title":"Heredofamilial juvenile muscular atrophy simulating muscular dystrophy","volume":"75","author":"Kugelberg","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"issue":"5\u20136","key":"10.1016\/bs.pmch.2018.12.003_bb0120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.003_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.pmch.2018.12.003_bb0135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/hmg\/9.5.849","article-title":"Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy","volume":"9","author":"Frugier","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.003_bb0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003468","article-title":"Development of a single vector system that enhances trans-splicing of SMN2 transcripts","volume":"3","author":"Coady","year":"2008","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.003_bb0165","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1089\/hum.2008.067","article-title":"A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo","volume":"19","author":"Dickson","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0170","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"6197","key":"10.1016\/bs.pmch.2018.12.003_bb0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2012.01.044","article-title":"Spinal muscular atrophy: the role of SMN in axonal mRNA regulation","volume":"1462","author":"Fallini","year":"2012","journal-title":"Brain Res"},{"issue":"18","key":"10.1016\/bs.pmch.2018.12.003_bb0185","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/bs.pmch.2018.12.003_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0955-0674(02)00332-0","article-title":"The SMN complex, an assemblyosome of ribonucleoproteins","volume":"14","author":"Paushkin","year":"2002","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-6-6","article-title":"A novel cell immunoassay to measure survival of motor neurons protein in blood cells","volume":"6","author":"Kolb","year":"2006","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0205","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1517\/13543784.2015.1038341","article-title":"Investigational therapies for the treatment of spinal muscular atrophy","volume":"24","author":"Kaczmarek","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"10.1016\/bs.pmch.2018.12.003_bb0210","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","article-title":"Small molecules in development for the treatment of spinal muscular atrophy","volume":"59","author":"Calder","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0215","author":"AveXis Communication of FDA BLA Submission"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/bs.pmch.2018.12.003_bb0235","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"15","key":"10.1016\/bs.pmch.2018.12.003_bb0240","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"7367","key":"10.1016\/bs.pmch.2018.12.003_bb0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.pmch.2018.12.003_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87908","article-title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy","volume":"1","author":"Powis","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-017-0613-5","article-title":"Cardiac pathology in spinal muscular atrophy: a systematic review","volume":"12","author":"Wijngaarde","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"10063","key":"10.1016\/bs.pmch.2018.12.003_bb0260","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/bs.pmch.2018.12.003_bb0265","first-page":"581","article-title":"A semi-mechanistic population pharmacokinetic model of Nusinersen: an antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"7","author":"Biliouris","year":"2018","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.003_bb0270","doi-asserted-by":"crossref","first-page":"e0139950\/1","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0275","author":"FDA label"},{"issue":"7","key":"10.1016\/bs.pmch.2018.12.003_bb0280","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0285","series-title":"Preparation of 1,4-disubstituted pyridazine analogs and methods for treating SMN deficiency related conditions","first-page":"p. 215","author":"Cheung","year":"2014"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0290","series-title":"Preparation of 1,4-disubstituted pyridazine analogs and methods for treating SMN-deficiency related conditions","first-page":"p. 158","author":"Cheung","year":"2015"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0295","series-title":"Preparation of thiadiazole analogs for treating SMN-deficiency-related-conditions","first-page":"p. 118","author":"Axford","year":"2014"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0300","series-title":"Sulfur-halogen intramolecular conformational constraints: identification of 1,3,4-thiadiazole analogs of LMI070 as SMN2 splicing modulators","author":"Sung","year":"2018"},{"issue":"20","key":"10.1016\/bs.pmch.2018.12.003_bb0305","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1093\/hmg\/dds285","article-title":"Characterization of behavioral and neuromuscular junction phenotypes in a novel allelic series of SMA mouse models","volume":"21","author":"Osborne","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.expneurol.2008.02.025","article-title":"Identification of a battery of tests for drug candidate evaluation in the SMN\u03947 neonate model of spinal muscular atrophy","volume":"212","author":"El-Khodor","year":"2008","journal-title":"Exp Neurol"},{"issue":"2","key":"10.1016\/bs.pmch.2018.12.003_bb0315","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI72017","article-title":"Requirement of enhanced survival Motoneuron protein imposed during neuromuscular junction maturation","volume":"124","author":"Kariya","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0320","series-title":"NCT02268552: an open label study of LMI070 (Branaplam) in type 1 spinal muscular atrophy (SMA)","author":"ClinicalTrials.gov","year":"2014"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0325","series-title":"Community update on the study of LMI070","author":"Novartis Press Release","year":"2016"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0330","series-title":"Update on LMI070 (branaplam) clinical trial","author":"Novartis Press Release","year":"2017"},{"issue":"13","key":"10.1016\/bs.pmch.2018.12.003_bb0335","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.6b00460","article-title":"Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 as a treatment for spinal muscular atrophy","volume":"59","author":"Woll","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0340","series-title":"Preparation of substituted chromenones for treating spinal muscular atrophy","first-page":"p. 468","author":"Woll","year":"2013"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0345","series-title":"Compounds for treating spinal muscular atrophy","first-page":"p. 278","author":"Lee","year":"2013"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0350","series-title":"Preparation of isochromenone derivatives for treating spinal muscular atrophy","first-page":"p. 243","author":"Chen","year":"2013"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0355","series-title":"Preparation of pyridopyrimidine derivatives and related compounds for treating spinal muscular atrophy","first-page":"p. 547","author":"Qi","year":"2013"},{"issue":"13","key":"10.1016\/bs.pmch.2018.12.003_bb0360","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1021\/acs.jmedchem.6b00459","article-title":"Specific correction of alternative survival motor neuron 2 splicing by small molecules: discovery of a potential novel medicine to treat spinal muscular atrophy","volume":"59","author":"Ratni","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0365","series-title":"NCT02240355: a study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (Moonfish)","author":"ClinicalTrials.gov","year":"2015"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0370","series-title":"Phase 2 data from spinal muscular atrophy program presented at the 20th international annual congress of the world muscle society","author":"PTC Therapeutics Press Release","year":"2015"},{"issue":"10","key":"10.1016\/bs.pmch.2018.12.003_bb0375","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1021\/acs.jmedchem.7b00406","article-title":"Discovery of a novel class of survival motor neuron 2 splicing modifiers for the treatment of spinal muscular atrophy","volume":"60","author":"Pinard","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0380","series-title":"Preparation of N-heteroaryl amides for treating spinal muscular atrophy","first-page":"p. 96","author":"Pinard","year":"2014"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0385","series-title":"Preparation of N-(imidazo[1,2-a]pyrazin-1-yl)benzamide and N-(imidazo[1,2-a]pyrazin-1-yl)pyridinecarboxamide compounds for treating spinal muscular atrophy","first-page":"p. 95","author":"Green","year":"2015"},{"issue":"15","key":"10.1016\/bs.pmch.2018.12.003_bb0390","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a selective survival of motor Neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0395","series-title":"2-(Imidazo[1,2-b]pyridazin-6-yl)pyrido[1,2a]pyrimidin-4-one derivatives as SMN modulators and their preparation and use for the treatment of spinal muscular atrophy","first-page":"p. 80","author":"Ratni","year":"2015"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0400","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S46.007","article-title":"Relationship between central and peripheral SMN protein increase upon treatment with RO7034067 (RG7916)","author":"Poirier","year":"2018"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0405","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0410","series-title":"NCT02633709: a study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7034067 (RG7916) given by mouth in healthy volunteers","author":"ClinicalTrials.gov","year":"2016"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0415","series-title":"NCT02908685: a study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in Type 2 and 3 spinal muscular atrophy participants (Sunfish)","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0420","series-title":"NCT02913482: a study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with Type 1 spinal muscular atrophy (Firefish)","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0425","series-title":"NCT03032172: a study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish)","author":"ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/bs.pmch.2018.12.003_bb0430","series-title":"Roche announces new data for risdiplam in spinal muscular atrophy (SMA) at the world muscle society congress","author":"F. Hoffmann-La Roche Ltd Press Release","year":"2018"},{"issue":"1","key":"10.1016\/bs.pmch.2018.12.003_bb0435","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/bs.pmch.2018.12.003_bb0440","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1515\/BC.2007.159","article-title":"FOXM1, a typical proliferation-associated transcription factor","volume":"388","author":"Wierstra","year":"2007","journal-title":"Biol Chem"},{"issue":"8","key":"10.1016\/bs.pmch.2018.12.003_bb0445","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/carcin\/bgt134","article-title":"C-terminus-deleted FoxM1 is expressed in cancer cell lines and induces chromosome instability","volume":"34","author":"Kim","year":"2013","journal-title":"Carcinogenesis"},{"issue":"16","key":"10.1016\/bs.pmch.2018.12.003_bb0450","doi-asserted-by":"crossref","first-page":"11715","DOI":"10.1074\/jbc.M701085200","article-title":"MADD\/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation: knockdown enhances trail-induced apoptosis of cancer cells","volume":"282","author":"Mulherkar","year":"2007","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/bs.pmch.2018.12.003_bb0455","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1093\/nar\/gkr203","article-title":"Cryptic splice sites and split genes","volume":"39","author":"Kapustin","year":"2011","journal-title":"Nucleic Acids Res"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646818300171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646818300171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T13:38:05Z","timestamp":1720964285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646818300171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780444642776"],"references-count":88,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2018.12.003","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}